COVID-19 disease. COVID-19, virus not identified
Conditions
Interventions
Intervention 1: Intervention group: Favipiravir (Zhejiang Hisun, China) plus Interferon beta-1a (CinnaGen, Iran). This group will receive 1600 mg Favipiravir twice a day for the first day and 600 mg t
Sponsors
Bandare-abbas University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age =18 years Positive polymerase chain reaction (PCR) test for COVID-19 Primary clinical symptoms Hospitalized Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm
Exclusion criteria
Exclusion criteria: Underlying diseases, including chronic hepatitis, cirrhosis, cholestatic liver diseases, cholecystitis, and peptic ulcers Acute and chronic renal failure Peptic ulcers History of allergy to studied drugs Pregnancy and breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Viral load. Timepoint: Before intervention and day 7 after the intervention?. Method of measurement: Polymerase chain reaction (PCR) test.;Body temperature. Timepoint: Before intervention and daily during the study. Method of measurement: Thermometer.;Oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: Pulse oximeter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of hospitalization. Timepoint: Time period from admission to discharge. Method of measurement: Patient's file.;C-reactive protein. Timepoint: Before intervention and day 7 after the intervention. Method of measurement: C-RP kit.;Incidence of serious adverse events. Timepoint: Before intervention and daily during the study. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Fathalipour
Bandare-abbas University of Medical Sciences
Outcome results
None listed